TORC - resTORbio, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
12.81
+0.75 (+6.24%)
As of 2:17PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close12.06
Open11.86
Bid12.5100 x 800
Ask12.5800 x 1800
Day's Range11.82 - 13.16
52 Week Range7.55 - 21.10
Volume35,246
Avg. Volume100,755
Market Cap359.459M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.6720
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.75
Trade prices are not sourced from all markets
  • GlobeNewswire27 days ago

    resTORbio Reports Third Quarter 2018 Financial Results

    Additional positive data from Phase 2b trial further support RTB101’s potential in reducing the incidence of respiratory tract infections (RTIs) in high-risk elderly patients.

  • GlobeNewswirelast month

    resTORbio Co-Founder and Chief Medical Officer Joan Mannick, M.D., to Present on TORC1 Inhibition at The Gerontological Society of America 2018 Annual Scientific Meeting

    BOSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced that Joan Mannick, M.D., Co-Founder and Chief Medical Officer, will present at The Gerontological Society of America 2018 Annual Scientific Meeting (GSA 2018), November 14-18, 2018, in Boston. Dr. Mannick will deliver an oral presentation during a symposium session as part of the GSA 2018 Biological Sciences Program, which includes symposia and poster sessions focusing on the aging process at the molecular, cellular and organismal level and disease conditions related to or accompanying the aging process.

  • GlobeNewswirelast month

    resTORbio to Present at Upcoming Investor Conferences in November

    BOSTON, Nov. 07, 2018 -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and.

  • GlobeNewswirelast month

    resTORbio Appoints Michael Grissinger to its Board of Directors

    BOSTON, Nov. 06, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC), a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced the appointment of Michael Grissinger to its Board of Directors. “Michael Grissinger brings significant pharma experience to our Board of Directors.

  • GlobeNewswire2 months ago

    resTORbio Announces Additional RTB101 Phase 2b Data Demonstrating Decreased Incidence of Laboratory-Confirmed RTIs with Severe Symptoms, Total Infections and UTIs

    RTB101 10 mg once daily decreased incidence of laboratory-confirmed respiratory tract infections (RTIs) with severe symptoms by 52.1% vs. placebo (p=0.034) In addition to.

  • GlobeNewswire3 months ago

    resTORbio to Present at 2018 Cantor Fitzgerald Global Healthcare Conference

    BOSTON, Sept. 24, 2018-- resTORbio, Inc., a clinical-stage biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics ...

  • GlobeNewswire3 months ago

    resTORbio Appoints Meredith Manning as Chief Commercial Officer

    BOSTON, Sept. 18, 2018 (GLOBE NEWSWIRE) -- resTORbio, Inc. (TORC), a clinical biopharmaceutical company focused on helping people live healthier longer through the development and commercialization of novel therapeutics for the treatment of aging-related diseases, today announced the appointment of Meredith Manning as Chief Commercial Officer. “We are excited to welcome Meredith to our executive team at resTORbio,” said Chen Schor, President and CEO of resTORbio. “Meredith is an industry veteran with a deep background developing and implementing commercial strategies for a number of successful biotechnology and pharmaceutical companies.

  • ResTORbio (TORC) Continue to Surge Higher?
    Zacks4 months ago

    ResTORbio (TORC) Continue to Surge Higher?

    As of late, it has definitely been a great time to be an investor in resTORbio, Inc. (TORC)

  • 3 Healthcare Stocks That Skyrocketed 35% or More This Week: Are They Still Buys?
    Motley Fool4 months ago

    3 Healthcare Stocks That Skyrocketed 35% or More This Week: Are They Still Buys?

    These stocks jumped much higher over the last few days. But should investors jump on the bandwagon?

  • Why resTORbio Stock Is Seeing Solid Growth Today
    Market Realist5 months ago

    Why resTORbio Stock Is Seeing Solid Growth Today

    Today, resTORbio (TORC) is trading at $13.36, which represents ~48.28% growth compared to yesterday. On July 24, resTORbio stock closed at $9.01, which represents ~19% growth from its 52-week low of $7.54 on April 10. TORC hit its 52-week high of $21.09 on February 26. Today, resTORbio announced positive results from its Phase 2b trial of RTB101 to evaluate the safety and efficacy of the drug in older individuals who are at high risk of morbidity and mortality due to respiratory tract infections.

  • Why resTORbio, Inc. Stock Skyrocketed Today
    Motley Fool5 months ago

    Why resTORbio, Inc. Stock Skyrocketed Today

    The clinical-stage biotech reported some really good results for its lead pipeline candidate.